百心安－Ｂ (2185.HK)

1.600 0.000 (0.00%) 收市：03:04PM HKT

百心安－Ｂ

Building 4
Room 302, 3rd Floor No.590 Ruiqing Road East Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai
China
86 21 6879 8511
https://www.bio-heart.com

版塊: Healthcare
行業: Biotechnology
全職員工: 32

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Li Wang	Executive Chairman of the Board, CEO & GM	764.26k	無	1968
Mr. Yunqing Wang	CFO, Joint Company Secretary & Executive Director	1.26M	無	1985
Ms. Peili Wang	Financial Manager & Executive Director	814.99k	無	1984
Dr. Bradley Stewart Hubbard D.V.M., DVM	Chief Medical Officer	無	無	1959
Ms. Siu Ying Kwok	Joint Company Secretary	無	無	1985
Mr. Tao Cai	Chairperson of the Board of Supervisors & Head of Technology of BRS	174.87k	無	1987

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

公司管治

截至 無 止，百心安－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。